Recently, it was shown that the protease DPP4 reduces the infiltration of lymphocytes by cleaving and inactivating CCL5 and CXCL10 and that the inhibition of DPP4 improves tumour control and synergises with immune checkpoint therapies (ICBs) [53]. The gene discussed is DPP4; the disease is neoplasm.